Change in clinical management of sentinel lymph node location in early stage cervical cancer: the role of SPECT/CT.

Abstract:

OBJECTIVE:The aim of this study was to investigate the feasibility of the sentinel lymph node (SLN) identification with SPECT/CT lymphoscintigraphy imaging in the early stage invasive cervical cancer in patients undergoing radical hysterectomy and pelvic lymphadenectomy. METHODS:Between March 2007 and June 2009, a prospective consecutive study was designed for SLN mapping. Twenty-two patients with cervical cancer FIGO stage IB1 (n=20) or stage IIA1 (n=2) underwent SLN identification with preoperative SPECT/CT and planar images (technetium-99m colloid albumin injection around the tumor) and posterior intraoperative detection with both blue dye and a handheld or laparoscopic gamma probe. Complete pelvic lymphadenectomy was performed in all cases by open (n=2) or laparoscopic (n=20) surgery. RESULTS:In the present series, a total of 35 SLN were detected with planar images and 40 SLN were identified and well located by SPECT/CT lymphoscintigraphy (median 2.0 nodes per patient). In 5/22 patients (22.7%) SPECT/CT procedure improves the number of localized SLN. Intraoperatively, 57 SLNs were identified, with a median of 3 SLNs per patient by gamma probe (a total of 53 hot nodes) and a median of 2 nodes per patient after blue dye injection (a total of 42 blue nodes). Microscopic nodal metastases (eight nodes, corresponding to four patients) were confirmed in 18.18% of cases; all these lymph nodes were previously detected as SLN. The remaining 450 nodes, including SLNs, following complete pelvic lymphadenectomy, were histologically negative. CONCLUSIONS:Sentinel lymph node detection is improved by SPECT/CT imaging because of the increased number of SLN detected and the better tridimensional anatomic location, allowing easier intra-operative detection with gamma probe and showing, in this series, a 100% negative predictive value.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Díaz-Feijoo B,Pérez-Benavente MA,Cabrera-Diaz S,Gil-Moreno A,Roca I,Franco-Camps S,Fernández MS,García-Jiménez A,Xercavins J,Martínez-Palones JM

doi

10.1016/j.ygyno.2010.12.336

subject

Has Abstract

pub_date

2011-03-01 00:00:00

pages

353-7

issue

3

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(10)01219-9

journal_volume

120

pub_type

杂志文章
  • The diagnostic value of PET/CT for primary ovarian cancer--a prospective study.

    abstract:OBJECTIVES:To prospectively evaluate the diagnostic value of combined PET/CT in detecting a malignant tumor in patients with no previous cancer history, presenting with a pelvic mass. METHODS:From September 2004 to March 2006, 101 patients (median age=60 years, range=24-85 years) with a Risk of Malignancy Index (RMI)>...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.ygyno.2006.11.022

    authors: Risum S,Høgdall C,Loft A,Berthelsen AK,Høgdall E,Nedergaard L,Lundvall L,Engelholm SA

    更新日期:2007-04-01 00:00:00

  • Overexpression of kallikrein 10 in epithelial ovarian carcinomas.

    abstract:OBJECTIVE:We wanted to identify genes up-regulated in ovarian tumors that might serve as early markers for ovarian cancer. One promising focus is the family of genes that encode secreted proteases, which play essential roles in tumor invasion and metastasis. Kallikrein 10 (KLK10) is a member of the kallikrein family of...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/s0090-8258(03)00257-9

    authors: Shvartsman HS,Lu KH,Lee J,Lillie J,Deavers MT,Clifford S,Wolf JK,Mills GB,Bast RC Jr,Gershenson DM,Schmandt R

    更新日期:2003-07-01 00:00:00

  • Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.

    abstract:OBJECTIVE:The first-line chemotherapy for ovarian cancer is based on a combination of platinum and taxane. To date, no reliable predictive biomarker has been recognized that is capable of identifying patients with pre-existing resistance to these agents. Here, we have established an integrated database and identified t...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.01.006

    authors: Fekete JT,Ősz Á,Pete I,Nagy GR,Vereczkey I,Győrffy B

    更新日期:2020-03-01 00:00:00

  • Prognostic value of CA 125 in advanced ovarian cancer.

    abstract::CA 125 was measured during early chemotherapy in 121 patients with FIGO stage III or IV ovarian cancer to investigate if the antigen could be used as a prognostic parameter. CA 125 was determined before the start of chemotherapy and 1 month after the first, second, and third course. The antigen level before the start ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(92)90043-i

    authors: Mogensen O

    更新日期:1992-03-01 00:00:00

  • Overexpression of gelsolin in human cervical carcinoma and its clinicopathological significance.

    abstract:OBJECTIVES:Cervical carcinoma is the second most common cause of death from gynecological cancers worldwide. Knowledge of the molecular mechanisms underlying the tumorigenesis of cervical cancer cell, except human papilloma virus infection, is limited. METHODS:A microarray was used to study the differential expression...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2010.10.005

    authors: Liao CJ,Wu TI,Huang YH,Chang TC,Wang CS,Tsai MM,Hsu CY,Tsai MH,Lai CH,Lin KH

    更新日期:2011-01-01 00:00:00

  • Effect of lamin-A expression on migration and nuclear stability of ovarian cancer cells.

    abstract:OBJECTIVE:Nuclear lamina plays important roles in nuclear shape and mechanical stability. Many studies demonstrated that defects of lamin-A were associated with several diseases, but little research was found on its potential roles in ovarian cancer. METHODS:GEPIA and GEO database were used to analyze lamin-A in ovari...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2018.10.030

    authors: Wang Y,Jiang J,He L,Gong G,Wu X

    更新日期:2019-01-01 00:00:00

  • Placental leucine aminopeptidase (P-LAP) expression is associated with chemosensitivity in human endometrial carcinoma.

    abstract:OBJECTIVE:Although treatment for advanced or recurrent endometrial carcinoma has improved over recent years with the introduction of paclitaxel- and platinum-based chemotherapy, in most, the disease remains incurable because of resistance to chemotherapy. In the previous study, we have shown that placental leucine amin...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2004.07.054

    authors: Shibata K,Kikkawa F,Kondo C,Mizokami Y,Kajiyama H,Ino K,Nomura S,Mizutani S

    更新日期:2004-11-01 00:00:00

  • Role of PET or PET/CT in the post-therapy surveillance of uterine sarcoma.

    abstract:OBJECTIVE:To evaluate the clinical accuracy and clinical impact of positron emission tomography (PET) or positron emission tomography/computed tomography (PET/CT) in detecting and treating tumor recurrence in patients with treated uterine sarcoma. METHODS:Results of 36 patients who underwent PET or PET/CT in post-ther...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.01.030

    authors: Park JY,Kim EN,Kim DY,Suh DS,Kim JH,Kim YM,Kim YT,Nam JH

    更新日期:2008-05-01 00:00:00

  • The role of interstitial brachytherapy using template in locally advanced gynecological malignancies.

    abstract:OBJECTIVE:Brachytherapy plays a major role in the treatment of patients with carcinoma of the cervix. However, routine intracavitary brachytherapy may not be feasible or adequate to treat locally advanced disease. The purpose of this prospective study was to assess treatment outcome for patients with locally advanced g...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.ygyno.2005.06.001

    authors: Agrawal PP,Singhal SS,Neema JP,Suryanarayan UK,Vyas RK,Rathi AK,Bahadur AK

    更新日期:2005-10-01 00:00:00

  • Absence of PTEN repeat tract mutation in endometrial cancers with microsatellite instability.

    abstract:OBJECTIVE:PTEN, a tumor suppressor gene shown to be frequently mutated in endometrial cancers, has been suggested to be a target of microsatellite instability (MSI)-driven mutagenesis. We set out to investigate the relationship between MSI and PTEN mutation in a large series of primary endometrial carcinomas. METHODS:...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2000.5900

    authors: Cohn DE,Basil JB,Venegoni AR,Mutch DG,Rader JS,Herzog TJ,Gersell DJ,Goodfellow PJ

    更新日期:2000-10-01 00:00:00

  • Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine.

    abstract::A 20 year old with recurrent low-grade serous carcinoma (LGSC) is discussed. The differential diagnosis, pathology, epidemiology, treatment options are discussed. Focus on the molecular pathways of LGSC and the implications of the diagnosis on fertility are highlighted. ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2017.01.023

    authors: Cohn DE,Backes FJ,Wallbillich JJ,Bixel K,Crafton SM,Neff R,ElNaggar AC,Smith B,Suarez AA

    更新日期:2017-03-01 00:00:00

  • Adenocarcinoma of Skene's duct associated with a systemic coagulopathy.

    abstract::Adenocarcinoma of the urethra is a rare neoplasm which is believed to arise from the periurethral ducts. Four such cases have been diagnosed at our institution during the past 25 years and their clinical courses are summarized in this report. In one patient, a disseminated coagulopathy with a predominantly fibrinolyti...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(85)90034-4

    authors: Taylor RN,Lacey CG,Shuman MA

    更新日期:1985-10-01 00:00:00

  • Characterization of peripheral blood and ovarian cancer-infiltrating lymphocytes: effect of HIV infection on phenotypic expression and proliferative response.

    abstract::A study that focused on the identification of the phenotype and proliferative responses of peripheral blood and ovarian cancer-infiltrating lymphocytes in a patient with stage III ovarian cancer who had human immunodeficiency virus infection is presented. Monoclonal antibodies and flow cytometry were used to determine...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1994.1126

    authors: Guidozzi F,Reddy S,Wadee A

    更新日期:1994-05-01 00:00:00

  • Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study.

    abstract:OBJECTIVES:The objectives of this study were twofold: (1) to estimate the anti-tumor efficacy of CI-958 in patients with measurable platinum-resistant ovarian cancer; (2) to determine the nature and degree of toxicity of CI-958 in these patients. METHODS:Patients received CI-958 560 mg/m(2) intravenously every 3 weeks...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1006/gyno.2000.5984

    authors: Hoffman MA,Blessing JA,Morgan M

    更新日期:2000-12-01 00:00:00

  • Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer. Consolidative intraperitoneal cisplatin in ovarian cancer.

    abstract:OBJECTIVE:The aim of this study is to evaluate the efficacy of intraperitoneal cisplatin as consolidation treatment in epithelian ovarian cancer patients with complete pathologic response following front-line platin-based chemotherapy. PATIENTS AND METHODS:Thirty patients who had no evidence of disease as assessed by ...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.ygyno.2003.10.002

    authors: Topuz E,Eralp Y,Saglam S,Saip P,Aydiner A,Berkman S,Yavuz E

    更新日期:2004-01-01 00:00:00

  • Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.

    abstract:OBJECTIVES:The objectives of this study were to estimate the clinical response rate and toxicity of daily tamoxifen combined with intermittent weekly medroxyprogesterone acetate (MPA). METHODS:This study reports the results of 61 patients with measurable advanced or recurrent endometrial carcinoma enrolled on this stu...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/j.ygyno.2003.09.018

    authors: Whitney CW,Brunetto VL,Zaino RJ,Lentz SS,Sorosky J,Armstrong DK,Lee RB,Gynecologic Oncology Group study.

    更新日期:2004-01-01 00:00:00

  • Comparison of long-term survival of total abdominal radical hysterectomy and laparoscopy-assisted radical vaginal hysterectomy in patients with early cervical cancer: Korean multicenter, retrospective analysis.

    abstract:PURPOSE:The aim of this study was to compare survival outcomes of total abdominal radical hysterectomy (TARH) versus laparoscopy-assisted radical vaginal hysterectomy (LARVH) in stage IA2-IB2 cervical cancer. METHODS:812 patients who underwent RH between 2008 and 2017 were evaluated in 3 institutions. Progression-free...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.09.035

    authors: Kwon BS,Roh HJ,Lee S,Yang J,Song YJ,Lee SH,Kim KH,Suh DS

    更新日期:2020-12-01 00:00:00

  • Bax, Bcl-2, and p53 expression in endometrial cancer.

    abstract:BACKGROUND:It has not been fully clarified whether alteration of Bax and other apoptosis-relating proteins of Bcl-2 and p53 is involved in endometrial carcinogenesis. METHODS:A total of 56 frozen tissues, which included 14 normal endometria, 13 endometrial hyperplasias (10 without atypia and 3 with atypia), and 29 end...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2002.6742

    authors: Sakuragi N,Salah-eldin AE,Watari H,Itoh T,Inoue S,Moriuchi T,Fujimoto S

    更新日期:2002-09-01 00:00:00

  • Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium.

    abstract:OBJECTIVE:The study aims at identifying novel markers for circulating tumor cells (CTCs) in patients with epithelial ovarian cancer (EOC), and at evaluating their impact on outcome. METHODS:Microarray analysis comparing matched EOC tissues and peripheral blood leucocytes (N=35) was performed to identify novel CTC mark...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2012.09.021

    authors: Obermayr E,Castillo-Tong DC,Pils D,Speiser P,Braicu I,Van Gorp T,Mahner S,Sehouli J,Vergote I,Zeillinger R

    更新日期:2013-01-01 00:00:00

  • Recurrent and persistent squamous cell cervical carcinoma in women under age 35.

    abstract::Forty-five patients with invasive cervical squamous cell carcinoma were registered in the Tom Baker Cancer Centre from 1980 to 1985. The natural history of 22 patients (48.9%) who developed persistent or recurrent disease including 11 Stage IB, 8 Stage IIB, and 3 Stage IIIB is reported. Only one patient who had the un...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(88)90020-0

    authors: Stuart GC,Robertson DI,Fedorkow DM,Duggan MA,Nation JG

    更新日期:1988-06-01 00:00:00

  • Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers.

    abstract::Practice changing standardization of lower extremity lymphedema quantitative measurements with integrated patient reported outcomes will likely refine and redefine the optimal risk-reduction strategies to diminish the devastating limb-related dysfunction and morbidity associated with treatment of gynecologic cancers. ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2020.10.026

    authors: Russo S,Walker JL,Carlson JW,Carter J,Ward LC,Covens A,Tanner EJ 3rd,Armer JM,Ridner S,Hayes S,Taghian AG,Brunelle C,Lopez-Acevedo M,Davidson BA,Schaverien MV,Ghamande SA,Bernas M,Cheville AL,Yost KJ,Schmitz K,Coy

    更新日期:2021-02-01 00:00:00

  • HPV subtypes and immunological parameters of cervical cancer in Iceland during two time periods, 1958-1960 and 1995-1996.

    abstract:OBJECTIVE:Cervical cancer is a disease caused in part by an infection with an oncogenic subtype of human papillomavirus (HPV). In this study we analysed all cervical cancer samples diagnosed in Iceland during two periods, 1958-1960 and 1995-1996, and asked whether significant changes in viral or immunological parameter...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/s0090-8258(03)00053-2

    authors: Mikaelsdottir EK,Benediktsdottir KR,Olafsdottir K,Arnadottir T,Ragnarsson GB,Olafsson K,Sigurdsson K,Kristjansdottir GS,Imsland AK,Ogmundsdottir HM,Rafnar T

    更新日期:2003-04-01 00:00:00

  • Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.

    abstract:OBJECTIVE:To determine the overall survival and relative effect of multiple prognostic variables in cohorts of patients with advanced-stage ovarian cancer treated with platinum-based neoadjuvant chemotherapy in lieu of primary cytoreductive surgery. METHODS:Twenty-two cohorts of patients with Stage III and IV ovarian ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.ygyno.2006.06.025

    authors: Bristow RE,Chi DS

    更新日期:2006-12-01 00:00:00

  • A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaïve advanced ovarian cancer.

    abstract:OBJECTIVES:The objectives of this multicenter phase II study were to evaluate the effects of gemcitabine-paclitaxel-cisplatin combination chemotherapy on response rate, survival, and toxicity in patients with advanced epithelial ovarian cancer (AEOC). METHODS:Chemonaive AEOC patients with bidimensionally measurable di...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1016/j.ygyno.2005.03.032

    authors: Gupta SK,John S,Naik R,Arora R,Selvamani B,Fuloria J,Ganesh N,Awasthy BS

    更新日期:2005-07-01 00:00:00

  • Low-grade serous carcinoma: new concepts and emerging therapies.

    abstract::For the past several years, all women with epithelial ovarian cancer have been treated identically, whether in a clinical trial or off protocol. Over the past decade, we have come to appreciate the magnitude of the heterogeneity of ovarian cancer. The development of the binary grading system for serous carcinoma was a...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2013.05.021

    authors: Romero I,Sun CC,Wong KK,Bast RC Jr,Gershenson DM

    更新日期:2013-09-01 00:00:00

  • Does debulking surgery improve survival in biologically aggressive ovarian carcinoma?

    abstract::Aggressive tumor reduction surgery has been widely used in patients with advanced stage epithelial ovarian carcinoma before initiation of cytotoxic chemotherapy. No randomized controlled trial has been carried out to confirm the benefits of such procedures. To examine the role of cytoreductive surgery in the managemen...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1997.4839

    authors: Le T,Krepart GV,Lotocki RJ,Heywood MS

    更新日期:1997-11-01 00:00:00

  • Technique for precaval and laterocaval nodes excision at extraperitoneal paraaortic lymphadenectomy.

    abstract:STUDY OBJECTIVE:To describe our technique for excision of the pre-caval and laterocaval nodes using an extraperitoneal approach. This technique was developed to make the dissection and excision of the less accessible nodes in an easier and safer way by minimizing the risk of great vessels injury and bleeding. DESIGN:S...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2017.10.030

    authors: Gorostidi M,Villalain C,Ruiz R,Jaunarena I,Lekuona A

    更新日期:2018-01-01 00:00:00

  • Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers.

    abstract:OBJECTIVE:BRCA1 mutation carriers have a high rate of both breast and ovarian cancer. Tamoxifen is a selective estrogen receptor modulator (SERM), which is used for the treatment of primary breast cancer and for the prevention of contralateral breast cancer. Our objective is to assess if tamoxifen treatment is associat...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2009.06.012

    authors: Vicus D,Rosen B,Lubinski J,Domchek S,Kauff ND,Lynch HT,Isaacs C,Tung N,Sun P,Narod SA,Hereditary Ovarian Cancer Clinical Study Group.

    更新日期:2009-10-01 00:00:00

  • Tumor diameter as a predictor of lymphatic dissemination in endometrioid endometrial cancer.

    abstract:OBJECTIVES:To assess the utility of tumor diameter (TD) for predicting lymphatic dissemination (LD) and determining need for lymphadenectomy following diagnosis of endometrioid endometrial cancer. METHODS:Patients diagnosed with stage I-III endometrioid endometrial cancer during 2003-2013 who underwent pelvic or para-...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2016.02.017

    authors: Cox Bauer CM,Greer DM,Kram JJF,Kamelle SA

    更新日期:2016-05-01 00:00:00

  • Role of an early second-look laparotomy in ovarian cancer.

    abstract::Of a group of 68 patients treated with standard polychemotherapy (CAP-5), 52 were evaluated by an early second-look laparotomy, preferably after three cycles of treatment. Of 21 patients with initial tumor residuals smaller than 2 cm, only 5 had residual tumor, and of 31 patients with tumor larger than 2 cm, 27 had re...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(89)90055-3

    authors: van Lith JM,Bouma J,Aalders JG,Boonstra H,Sleijfer DT,Willemse PH

    更新日期:1989-11-01 00:00:00